Alethia Biotherapeutics Inc
Advertisement
Alethia Biotherapeutics Inc., based in Montréal, Québec, is focusing on cancer-associated epithelial to mesenchymal transition (EMT) with its clinical-stage monoclonal antibody, AB16B5. This innovative EMT inhibitor is designed to prevent chemotherapy resistance and metastatic tumor invasion in invasive carcinomas.
AB16B5 is a humanized IgG2 antibody that effectively blocks EMT, and preclinical data demonstrates its potential to enhance responses to standard chemotherapy while reducing tumor invasion in xenografted animal models. Alethia is committed to advancing this research to improve cancer treatment outcomes.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.
Advertisement